1 / 13

Technological Innovation for Health

Technological Innovation for Health. Abdallah S Daar McLaughlin-Rotman Centre for Global Health UHN/University of Toronto. Necessary ingredients Failures Success stories Empirical studies Innovative solutions. Necessary Ingredients. Operational access to good science

brinly
Download Presentation

Technological Innovation for Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Technological Innovation for Health Abdallah S Daar McLaughlin-Rotman Centre for Global Health UHN/University of Toronto

  2. Necessary ingredients • Failures • Success stories • Empirical studies • Innovative solutions

  3. Necessary Ingredients • Operational access to good science • Identification and prioritizing needs • Confidence in developing ideas • Supportive environment (policies, entrepreneurship, ideology, culture, private sector) • Tech transfer and IP systems • Total skill sets available for tech development, commercialization and marketing • Provision of capital: proof of principle, valley of death, venture capital • Supportive health systems capable of internalizing tech

  4. Failure : Hep B Vaccine • discovered- 1967 • 1st vaccine- 1969 • available- in U.S. 1982 Ulmer, J.B. and Liu, M.A. 2002. Ethical Issues for vaccines and immunization. Nat Rev Immunol 2 291-296

  5. Success: Cuba and Meningitis B Vaccine

  6. Success and Failure: A to Z

  7. Stagnant Technologies • Natural Products • Extraction ofArtemisia Annua: Tanzania • Tanzed: an anti-HIV protein based compound in Tanzania • Diagnostics • Dip-stick Schistosomiasis: Ghana • Rapid HIV Diagnostic Kits: Kenya • Mosquito Repellants: Nigeria , Kenya • Pyrethrum-based Mosquito Nets: Rwanda

  8. Empirical Studies: Ghana, Tanzania and Rwanda • Key findings based on a 110 interviews • Lack of synergy and knowledge flows between various stakeholders • Inadequate financial incentives/resources for commercialization • Unexploited potential to commercialize innovative products

  9. Innovative Solutions Held stakeholder workshops in Ghana, Tanzania and Rwanda with over 200 participants Our preliminary findings were validated and the concept of Convergence Innovation resonated with all stakeholders Developed business plans and presented them to Science Ministers Ministers appointed local steering committees to implement Convergence Platforms

  10. What is Convergence Innovation?

  11. How might a convergence centre be funded? “In particular the Bank should support the development of national and regional centers of excellence in the health sciences and in Energy and environmental technologies. There are significant potential benefits from strengthening the linkages between life sciences and the private sector. These centers would facilitate and incubate innovation, supporting entrepreneurship and developing technologies.”

  12. How Might Technologies Be Funded? • We identified very little venture capital invested into life sciences • IFC has announced a health venture fund for Africa • Plans to mobilize up to $1B, including an $350M equity vehicle with initial investments of $100M • Partnerships will be important to mitigate and tier risk and demonstrate that this market failure can be bridged

  13. Thank You Additional funding partners for the McLaughlin-Rotman Centre for Global Health can be found at www.mrcglobal.org Presentation Title / Date

More Related